FDG PET Introduction (What it is)
FDG PET is an imaging test that shows how tissues use glucose (sugar).
It uses a small amount of a radioactive glucose-like tracer called FDG.
FDG PET is commonly used in cancer care to look for active tumor sites in the body.
It is often performed as part of a combined scan such as PET/CT or PET/MRI.
Why FDG PET used (Purpose / benefits)
In oncology, clinicians often need more than anatomy (what a tumor looks like) to make decisions. They also need tumor activity information (how biologically “busy” the tumor appears). FDG PET helps address that gap by highlighting areas with higher-than-expected glucose uptake, which can be seen in many cancers.
Common goals of FDG PET in cancer care include:
- Detection: identifying suspicious sites that may represent cancer, especially when other tests are unclear.
- Staging: mapping how far a cancer has spread (for example, to lymph nodes or distant organs), which can affect overall treatment strategy.
- Treatment planning: supporting decisions about surgery, radiation fields, or systemic therapy (treatment that circulates throughout the body).
- Response assessment: evaluating whether a tumor is becoming less metabolically active after treatment, sometimes before size changes are obvious on CT or MRI.
- Restaging: assessing possible recurrence or progression after initial treatment.
- Clarifying equivocal findings: helping interpret abnormalities seen on CT, MRI, or other imaging when the significance is uncertain.
FDG PET does not replace biopsy when tissue confirmation is needed. Instead, it often complements pathology, clinical examination, and other imaging to provide a more complete picture.
Indications (When oncology clinicians use it)
Oncology teams may consider FDG PET in scenarios such as:
- Initial staging for certain cancers where PET findings commonly influence management (varies by cancer type and stage)
- Evaluating lymph node involvement when CT or MRI findings are borderline or unclear
- Looking for an unknown primary tumor when metastases are suspected but the starting site is not identified
- Assessing a pulmonary nodule or mass when the probability of malignancy is being clarified (case-dependent)
- Distinguishing residual tumor vs scar tissue after treatment in selected settings
- Measuring treatment response, including “interim” evaluation during therapy for some diseases (practice varies)
- Investigating suspected recurrence when symptoms, exams, or other tests raise concern
- Supporting radiation therapy planning by identifying metabolically active targets
- Evaluating certain hematologic malignancies (blood cancers) where FDG uptake patterns can inform assessment (varies by subtype)
Contraindications / when it’s NOT ideal
FDG PET is not always the best test for every patient or every cancer question. Situations where FDG PET may be avoided, delayed, or supplemented by another approach include:
- Pregnancy, because the test uses ionizing radiation (decisions are individualized)
- Inability to remain still or follow instructions during the scan, which can reduce image quality (sedation may be considered in selected cases)
- Markedly elevated blood glucose at the time of the scan, which can reduce FDG uptake in tumors and complicate interpretation
- Recent strenuous exercise or muscle activity, which can increase normal muscle uptake and create distracting findings
- Active infection or inflammation, which can also show increased FDG uptake and cause false-positive concern for cancer
- Tumors that are often less FDG-avid (less likely to take up FDG), where other imaging or other PET tracers may be more informative (varies by tumor type)
- Very small lesions, which may be difficult for PET to resolve depending on location and technical factors
- When a contrast-enhanced CT or MRI is specifically needed for detailed anatomy (FDG PET is frequently combined with CT, but protocols vary)
- When kidney function or contrast allergy limits the CT contrast portion (this relates to PET/CT with contrast, not FDG itself)
Clinicians choose imaging based on the clinical question, available modalities, and how results are expected to change management.
How it works (Mechanism / physiology)
FDG PET is a diagnostic imaging test, not a treatment. Its “mechanism” is based on tumor metabolism and how PET scanners detect radioactivity.
Key concepts include:
- FDG (fluorodeoxyglucose) is a glucose analog labeled with the radionuclide fluorine-18. After injection into a vein, FDG circulates and is taken up by cells that use glucose.
- Many cancers show increased glucose use, often explained by altered tumor metabolism (commonly described as the Warburg effect). This can lead to higher FDG uptake in tumor tissue compared with surrounding normal tissue.
- Once FDG enters a cell, it is phosphorylated and tends to become metabolically trapped, allowing it to accumulate in higher-uptake tissues during the imaging window.
- The PET scanner detects signals produced as the tracer decays, allowing reconstruction of a three-dimensional map of tracer distribution.
- Results are interpreted visually and may be quantified using measures such as the standardized uptake value (SUV). SUV can be helpful, but it is influenced by many factors (scanner protocols, timing, blood glucose, body composition), so it is not an absolute measure of “how bad” a cancer is.
Normal physiology matters. FDG uptake is commonly seen in:
- Brain (high baseline glucose use)
- Heart (variable, depending on physiology and preparation)
- Kidneys and bladder (FDG is excreted in urine)
- Liver and bowel (variable, often mild-to-moderate background activity)
- Muscles and brown fat (can increase with activity, cold exposure, or stress)
Because inflammation and healing can also increase FDG uptake, FDG PET findings must be interpreted in clinical context.
FDG PET Procedure overview (How it’s applied)
FDG PET is performed as an imaging appointment, most commonly as FDG PET/CT and, in some centers, FDG PET/MRI. Workflows vary by facility and clinical indication, but a typical pathway looks like this:
- Evaluation/exam: A clinician identifies a specific question (for example, staging, suspected recurrence, or response assessment) and reviews the patient’s history and prior imaging.
- Imaging/biopsy/labs: The PET team may review relevant labs and imaging. A blood glucose check near the scan time is common because glucose levels can affect FDG distribution.
- Tracer administration: FDG is injected through an IV line, followed by an uptake period where the tracer distributes in the body.
- Imaging acquisition: The patient lies on the scanner table while PET images are acquired, usually along with CT (or MRI) for anatomic localization.
- Staging: A radiologist or nuclear medicine physician interprets findings in the context of cancer staging systems (the staging method depends on cancer type).
- Treatment planning: Results may be reviewed in a multidisciplinary setting (for example, tumor board) to support decisions about surgery, radiation, systemic therapy, or additional testing.
- Intervention/therapy: FDG PET does not treat cancer, but it can influence where and how treatment is delivered.
- Response assessment: A later FDG PET may be used to evaluate metabolic response, depending on the cancer and treatment plan.
- Follow-up/survivorship: Imaging frequency and modality vary by clinician and case; FDG PET is not universally used for routine surveillance.
Types / variations
FDG PET is a technique, and its “types” usually reflect how the scan is combined with other imaging or how it is used clinically.
Common variations include:
- FDG PET/CT: The most widely used approach in oncology. CT helps localize PET findings anatomically and can identify structural changes such as enlarged nodes or organ lesions.
- FDG PET/MRI: Used in some centers, particularly when MRI provides advantages for soft tissue detail (for example, certain brain, liver, pelvis, or pediatric scenarios). Availability varies.
- Whole-body vs limited-field imaging: Many oncology scans cover from skull base to mid-thigh, while some indications require more complete coverage or a focused region (protocols vary).
- Baseline vs follow-up FDG PET: A baseline study may be compared with later scans to assess change over time.
- Response-adapted imaging: In selected cancers, interim PET results may be incorporated into response assessment strategies (practice varies by disease and institution).
- Adult vs pediatric FDG PET: Pediatric protocols may differ in dose calculation, preparation, and the need for sedation to reduce motion (case-dependent).
- Problem-solving FDG PET: Used to clarify an indeterminate lesion seen on another study, recognizing that false positives and false negatives are possible.
Other PET tracers exist, but they are not FDG PET. Clinicians may consider alternative tracers when the biology of the cancer makes FDG less informative.
Pros and cons
Pros:
- Helps assess metabolic activity, not just size or shape
- Can identify occult disease (sites not obvious on anatomic imaging) in selected situations
- Supports staging and restaging, which can change treatment strategy
- Useful for response assessment in some cancers, sometimes before size changes occur
- Provides whole-body surveying in a single exam (protocol-dependent)
- Often improves anatomic localization when combined with CT or MRI
- Can help guide biopsy targeting by identifying more active areas (case-dependent)
Cons:
- Not cancer-specific: infection, inflammation, and healing can mimic malignancy
- Variable sensitivity across tumor types; some cancers are less FDG-avid (varies by cancer type and stage)
- Limited spatial resolution: very small lesions may be missed
- Radiation exposure from the PET tracer and, for PET/CT, from CT (dose varies by protocol)
- Results can be affected by blood glucose levels, recent activity, and technical factors
- May lead to incidental findings that require additional evaluation
- Access and scheduling can be limited in some regions, and insurance coverage rules vary
Aftercare & longevity
FDG PET itself does not create a long-term effect in the body; it is a diagnostic study, and the tracer decays over time. “Aftercare” is usually minimal and focuses on practical next steps.
What matters most after an FDG PET is how results are integrated into the overall cancer-care plan:
- Cancer type and stage strongly influence how PET findings are interpreted and whether additional tests are needed.
- Tumor biology (how aggressive the tumor behaves and how it uses glucose) affects how “bright” lesions appear and how reliable FDG PET is for that cancer.
- Recent treatments (surgery, radiation, immunotherapy, chemotherapy) can change uptake patterns due to inflammation, healing, or immune activation; timing of imaging may affect interpretation.
- Comorbidities such as diabetes, infection, or inflammatory disease can influence background uptake and the likelihood of false-positive findings.
- Follow-up strategy varies. Some patients will have additional imaging, tissue sampling, or treatment adjustments, while others may continue with the existing plan if findings are reassuring.
- Supportive care and survivorship services (rehabilitation, nutrition, symptom management, psychosocial support) can affect overall outcomes, even though they do not change the scan itself.
If an FDG PET result is unexpected or unclear, clinicians often correlate it with prior imaging, symptoms, physical examination, laboratory tests, and—when appropriate—biopsy.
Alternatives / comparisons
FDG PET is one tool among many. Alternatives or complementary approaches depend on the clinical question.
Common comparisons include:
- CT: Strong for anatomic detail, lung evaluation, and size-based measurements. CT may miss early metabolic changes that PET can detect, while PET can miss tiny lesions that CT can sometimes visualize.
- MRI: Excellent soft tissue contrast and useful in brain, liver, pelvis, and musculoskeletal imaging. MRI provides detailed anatomy and certain functional sequences, but it does not measure FDG uptake.
- Ultrasound: Useful for targeted evaluation (thyroid, lymph nodes, abdomen) and for guiding biopsy, but it is not a whole-body metabolic survey.
- Bone scan: Used to evaluate skeletal metastases for some cancers. FDG PET can detect many bone lesions as well, but performance varies by tumor type and by whether lesions are lytic or sclerotic.
- Biopsy (pathology): Provides definitive tissue diagnosis and molecular testing when needed. PET cannot confirm histology; it identifies patterns of uptake that may suggest where to biopsy.
- Other PET tracers: In selected cancers, non-FDG tracers may better match tumor biology. The choice depends on local availability and the clinical indication.
- Observation/active surveillance: For some findings or low-risk scenarios, careful follow-up with repeat exams or imaging may be chosen rather than immediate additional testing (case-dependent).
- Treatment approaches (surgery, radiation, systemic therapy, clinical trials): FDG PET does not replace therapy; it can help inform whether disease appears localized or systemic and whether response is occurring, which may influence treatment selection.
The best comparison is usually “Which test most directly answers the current clinical question?” rather than which test is “better” overall.
FDG PET Common questions (FAQ)
Q: Is an FDG PET scan painful?
Most people feel only a brief needle stick for the IV placement and tracer injection. The scan itself is typically not painful. Lying still can be uncomfortable for some, especially with pain or limited mobility.
Q: Will I need anesthesia or sedation?
Most adults do not need anesthesia. Sedation may be considered for people who cannot remain still due to anxiety, claustrophobia, or certain medical conditions, and it is more common in some pediatric cases. The approach varies by center and patient factors.
Q: How long does FDG PET take?
The appointment includes preparation, a tracer uptake period, and the scan itself. Many patients complete the full visit in a single session. Exact timing depends on the facility protocol and whether the exam includes a CT or MRI component.
Q: Is FDG PET safe? What about radiation exposure?
FDG PET uses ionizing radiation from the tracer and often from the CT portion of PET/CT. In healthcare, radiation-based imaging is typically chosen when the expected diagnostic benefit is considered to outweigh potential risk. Individual considerations include age, pregnancy status, and the need for repeat imaging.
Q: What side effects can happen from the FDG tracer?
Side effects from FDG are uncommon, and allergic reactions are considered rare. Discomfort is more often related to IV placement than the tracer itself. If IV contrast is used for the CT portion, contrast-related risks are separate and depend on kidney function and allergy history.
Q: Can FDG PET show false positives or false negatives?
Yes. Inflammation, infection, and healing tissue can show increased FDG uptake that may mimic cancer. Some cancers and some small lesions may show low uptake and be less visible, so results must be interpreted alongside clinical history and other tests.
Q: How much does FDG PET cost?
Costs vary widely depending on the country, healthcare system, scan type (PET/CT vs PET/MRI), use of contrast, and insurance coverage. Facilities often provide pre-authorization support and an estimate when scheduling. Out-of-pocket costs and coverage rules differ by plan.
Q: Can I go back to work or normal activities afterward?
Many people return to usual activities the same day. Some centers provide guidance about limiting close contact for a short period with infants or pregnant people due to residual radioactivity, but recommendations vary. Activity restrictions may also depend on sedation use or other individual factors.
Q: Does FDG PET affect fertility or pregnancy?
FDG PET involves radiation exposure, so pregnancy status is an important consideration and is typically discussed before the scan. Fertility effects from a diagnostic PET scan are not a typical clinical concern, but reproductive planning questions are best addressed with the oncology and imaging team. Decisions are individualized based on urgency and alternatives.
Q: How are results used, and what happens next?
A specialist interprets the scan and issues a report that is reviewed by the treating team. Next steps might include correlating with prior imaging, ordering additional tests, adjusting staging, planning radiation fields, selecting systemic therapy, or recommending biopsy of a specific site. Follow-up timing and strategy vary by cancer type and stage.